Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384200 | 0.92 | EGFR (0.38) | ADORA2AEGFRDHODHPTGIRFBP1 | |
| SCHEMBL4387719 | 0.91 | L3MBTL1 (0.35) | EGFRPTGIRFBP1FYN | |
| SCHEMBL4383980 | 0.86 | PTGIR (0.39) | EGFRPTGIR | |
| SCHEMBL4387626 | 0.86 | PTGIR (0.33) | EGFRDHODHPTGIR | |
| SCHEMBL4378282 | 0.85 | PTGIR (0.35) | EGFRPTGIR | |
| SCHEMBL4384051 | 0.84 | GCGR (0.35) | EGFR | |
| SCHEMBL4389505 | 0.83 | PTGIR (0.36) | EGFRPTGIR | |
| SCHEMBL4381492 | 0.82 | PTGIR (0.36) | EGFRPTGIRFBP1 | |
| SCHEMBL4385894 | 0.81 | EGFR (0.41) | EGFRDHODHDPP4CAPN1FABP3 | |
| SCHEMBL4379007 | 0.80 | ADORA2A (0.44) | ADORA2ADPP4PTGIRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | ADORA2A 3962/4885EGFR 624/4885DHODH 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.